<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421017</url>
  </required_header>
  <id_info>
    <org_study_id>11-00598</org_study_id>
    <secondary_id>1R01CA161891-01</secondary_id>
    <nct_id>NCT01421017</nct_id>
  </id_info>
  <brief_title>Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases</brief_title>
  <official_title>Phase I/II Study of TLR7 Agonist Imiquimod, Cyclophosphamide, and Radiotherapy in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test
      the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and
      radiotherapy (RT) in patients with skin metastases from breast cancer in the second part
      (Phase II). Currently this trial is in its Phase II part.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By harnessing the cytocidal and immunostimulatory properties of two local treatment
      modalities, RT and IMQ, an effective, adaptive immune response can be generated, resulting in
      systemic control of metastatic breast cancer after local treatment of cutaneous metastases.
      Additionally, based on investigators' recent preclinical data, the investigators intend to
      estimate in patients with metastatic breast cancer, if the addition of immunomodulatory
      cyclophosphamide can increase anti-tumor responses.

      This trial originally had one treatment arm IMQ/RT(patients were treated with IMQ and RT).
      Recent evidence has emerged that the addition of immunomodulatory cyclophosphamide (CTX)
      increased anti-tumor responses, therefore the IMQ/RT arm is closed and the trial will
      continue with two additional cohorts (CTX/IMQ/RT and CTX/RT) which include cyclophosphamide.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systemic tumor response rates (Complete Response+Partial Response)</measure>
    <time_frame>9 weeks from the start of the treatment of RT</time_frame>
    <description>The systemic tumor response refers to the response at the time of best overall response. The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok, et al., 2009).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tumor response rates (Clinical Complete Response+Partial Response)</measure>
    <time_frame>9 weeks from the start of the treatment</time_frame>
    <description>The response refers to the best overall response, based on European Organization for Research and Treatment of Cancer's definitions for chest wall tumors (Kouloulias, et al., 2002).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IMQ+RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm has been closed as of 6/4/2014.
Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)
Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.
Week 9: response assessment
Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTX/IMQ/RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion
Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)
Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.
Week 9: response assessment
Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTX/RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients with only non-skin metastatic sites
First cycle (Cycle 1):
Week -1 (day -7): cyclophosphamide 200mg/m2 IV as single infusion
Weeks 1-2: RT given to one site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)
Week 9: response assessment
Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <arm_group_label>IMQ+RT</arm_group_label>
    <arm_group_label>CTX/IMQ/RT</arm_group_label>
    <arm_group_label>CTX/RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <arm_group_label>IMQ+RT</arm_group_label>
    <arm_group_label>CTX/IMQ/RT</arm_group_label>
    <other_name>ALDARA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>CTX/IMQ/RT</arm_group_label>
    <arm_group_label>CTX/RT</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with biopsy-confirmed breast cancer.

          2. Patients with at least measurable skin metastases and distant, measurable metastases
             (outside of skin) by Response Evaluation Criteria in Solid Tumors (RECIST). For
             patients without distant measurable metastases, an area of the skin metastases
             designated to not receive local therapy can be substituted. Patients with multiple (&gt;=
             2) metastatic sites (skin involvement not required), with at least one site measurable
             by RECIST, will be eligible for the CTX/RT cohort.

          3. Age &gt;= 18 years.

          4. Eastern Cooperative Oncology Group performance status 0-2.

          5. Patients must agree to tumor fine-needle aspiration required by protocol.

          6. Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) can be
             continued if distant metastases are non-responsive (i.e. no complete response or
             partial response) on that regimen for &gt;= 8 weeks as assessed by the investigator.

          7. Patients must have adequate organ and bone marrow function as defined below:

               -  absolute neutrophil count &gt;= 1,300/microliter

               -  hemoglobin &gt;= 9.0 grams/deciliter

               -  platelets &gt;= 75,000/microliter

               -  total bilirubin =&lt; 1.5 X institutional upper limit of normal

               -  AST (aspartate aminotransferase) =&lt; 2.5 X institutional upper limit of normal

               -  ALT (alanine aminotransferase) =&lt; 2.5 X institutional upper limit of normal

               -  creatinine =&lt; 2 X institutional upper limit of normal if patient has chronic
                  renal insufficiency and creatinine has been stable for &gt; 4 months)

          8. Informed consent.

        Exclusion Criteria:

          1. Brain metastases unless resected or irradiated and stable &gt;= 4 weeks.

          2. Concurrent treatment with other investigational agents.

          3. Patients who have received any local therapy (radiotherapy, high-potency
             corticosteroids, intralesional therapy, laser therapy or surgery) other than biopsy to
             the target area within 4 weeks prior to first dosing of study agent.

          4. Patients who have received hyperthermia to the target area within 10 weeks prior to
             first dosing of study agent.

          5. Patients with an uncontrolled bleeding disorder.

          6. Patients (with skin metastases only) who will be therapeutically anticoagulated with
             heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation
             can be held prior to biopsy as per investigator). Patients on aspirin and other
             platelet agents are eligible.

          7. Patients with known immunodeficiency or receiving immunosuppressive therapies.

          8. History of allergic reactions to imiquimod or its excipients.

          9. Uncontrolled intercurrent medical illness or psychiatric illness/social situations
             that would limit compliance with study requirements.

         10. Pregnancy or lactation.

         11. Women of childbearing potential not using a medically acceptable means of
             contraception.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb√© C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.</citation>
    <PMID>19934295</PMID>
  </reference>
  <reference>
    <citation>Kouloulias VE, Dardoufas CE, Kouvaris JR, Gennatas CS, Polyzos AK, Gogas HJ, Sandilos PH, Uzunoglu NK, Malas EG, Vlahos LJ. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin Cancer Res. 2002 Feb;8(2):374-82.</citation>
    <PMID>11839652</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation therapy</keyword>
  <keyword>combination therapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>immune response modifier</keyword>
  <keyword>immunostimulatory</keyword>
  <keyword>immunomodulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

